Evidence map›Paper›PMID 39799207›Full record

ArticleScientific reports2025

Obtaining personalized predictions from a randomized controlled trial on Alzheimer's disease.

Dennis Shen, Anish Agarwal, Vishal Misra, Bjoern Schelter, Devavrat Shah, Helen Shiells, Claude Wischik

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dennis ShenDepartment of Data Sciences and Operations, USC, Los Angeles, USA. dennis.shen@marshall.usc.edu.
Anish AgarwalDepartment of Industrial Engineering and Operations Research, Columbia University, New York, USA.
Vishal MisraDepartment of Computer Science, Columbia University, New York, USA.
Bjoern SchelterTauRx Therapeutics, Aberdeen, Scotland.
Devavrat ShahDepartment of Electrical Engineering and Computer Science, MIT, Cambridge, USA.
Helen ShiellsTauRx Therapeutics, Aberdeen, Scotland.
Claude WischikTauRx Therapeutics, Aberdeen, Scotland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this article is to infer patient level outcomes from population level randomized control trials (RCTs). In this pursuit, we utilize the recently proposed synthetic nearest neighbors (SNN) estimator. At its core, SNN leverages information across patients to impute missing data associated with each patient of interest. We focus on two types of missing data: (i) unrecorded outcomes from discontinuing the assigned treatments and (ii) unobserved outcomes associated with unassigned treatments. Data imputation in the former powers and de-biases RCTs, while data imputation in the latter simulates "synthetic RCTs" to predict the outcomes for each patient under every treatment. The SNN estimator is interpretable, transparent, and causally justified under a broad class of missing data scenarios. Relative to several standard methods, we empirically find that SNN performs well for the above two applications using Phase 3 clinical trial data on patients with Alzheimer's Disease. Our findings directly suggest that SNN can tackle a current pain point within the clinical trial workflow on patient dropouts and serve as a new tool towards the development of precision medicine. Building on our insights, we discuss how SNN can further generalize to real-world applications.

Indexed as

Alzheimer DiseasePrecision MedicineRandomized Controlled Trials as TopicHumansTreatment OutcomeDropoutsPrecision medicineReal-world dataReal-world evidenceSynthetic trials

Identifiers

PMID39799207
PMCPMC11724978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.